| Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Leon Francisco | Chief Scientific Officer | Feb 13 | Option Exercise | 2.50 | 25,985 | 64,962 | 1,598,985 | Feb 14 07:19 PM | | Palmer Ashleigh | Director and CEO | Feb 13 | Option Exercise | 2.50 | 25,835 | 64,588 | 2,595,885 | Feb 14 07:13 PM | | Leon Francisco | Chief Scientific Officer | Feb 13 | Sale | 10.04 | 25,985 | 260,944 | 1,573,000 | Feb 14 07:19 PM | | Palmer Ashleigh | Director and CEO | Feb 13 | Sale | 10.04 | 25,835 | 259,448 | 2,570,050 | Feb 14 07:13 PM | | Palmer Ashleigh | Director and CEO | Feb 10 | Option Exercise | 2.50 | 50,000 | 125,000 | 2,620,050 | Feb 14 07:13 PM | | Leon Francisco | Chief Scientific Officer | Feb 10 | Option Exercise | 2.50 | 50,000 | 125,000 | 1,623,000 | Feb 14 07:19 PM | | Leon Francisco | Chief Scientific Officer | Feb 10 | Sale | 10.11 | 50,000 | 505,605 | 1,573,000 | Feb 14 07:19 PM | | Palmer Ashleigh | Director and CEO | Feb 10 | Sale | 10.11 | 50,000 | 505,555 | 2,570,050 | Feb 14 07:13 PM | | Hoitt Jason | Chief Commercial Officer | Feb 10 | Sale | 10.00 | 4,500 | 45,005 | 0 | Feb 14 07:16 PM | | Palmer Ashleigh | Director and CEO | Jan 18 | Option Exercise | 2.50 | 24,165 | 60,412 | 2,594,215 | Jan 20 08:00 PM | | Leon Francisco | Chief Scientific Officer | Jan 18 | Option Exercise | 2.50 | 24,015 | 60,038 | 1,597,015 | Jan 20 08:00 PM | | Sessa Capital (Master), L.P. | 10% Owner | Jan 18 | Sale | 9.40 | 3,000,000 | 28,200,000 | 11,879,023 | Jan 20 04:10 PM | | Palmer Ashleigh | Director and CEO | Jan 18 | Sale | 10.27 | 24,165 | 248,063 | 2,570,050 | Jan 20 08:00 PM | | Leon Francisco | Chief Scientific Officer | Jan 18 | Sale | 10.27 | 24,015 | 246,584 | 1,573,000 | Jan 20 08:00 PM | | Leon Francisco | Chief Scientific Officer | Dec 29 | Option Exercise | 2.50 | 187,000 | 467,500 | 1,760,000 | Dec 30 04:01 PM | | Leon Francisco | Chief Scientific Officer | Dec 29 | Sale | 10.26 | 187,000 | 1,918,601 | 1,573,000 | Dec 30 04:01 PM | | Leon Francisco | Chief Scientific Officer | Dec 27 | Option Exercise | 2.50 | 10,674 | 26,685 | 1,583,674 | Dec 29 04:01 PM | | Leon Francisco | Chief Scientific Officer | Dec 27 | Sale | 10.00 | 10,674 | 106,740 | 1,573,000 | Dec 29 04:01 PM | | Leon Francisco | Chief Scientific Officer | Dec 23 | Option Exercise | 2.50 | 375 | 938 | 1,573,375 | Dec 27 05:51 PM | | Leon Francisco | Chief Scientific Officer | Dec 23 | Sale | 10.00 | 375 | 3,750 | 1,573,000 | Dec 27 05:51 PM | | Leon Francisco | Chief Scientific Officer | Dec 22 | Option Exercise | 2.50 | 1,568 | 3,920 | 1,574,568 | Dec 27 05:51 PM | | Leon Francisco | Chief Scientific Officer | Dec 22 | Sale | 10.00 | 1,568 | 15,681 | 1,573,000 | Dec 27 05:51 PM |
|
